Foundation Supports Legislation Backing Cancer Treatment Coverage

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

NEWPORT NEWS, Va-A new organization, the National Patient Advocate Foundation (NPAF), has been created to support bills favoring patient access to insurance funding and encourage legislation on issues that threaten cancer patients' coverage for evolving therapies, therapeutic devices, or agents prescribed by their treating physicians.

NEWPORT NEWS, Va—A new organization, the National Patient Advocate Foundation (NPAF), has been created to support bills favoring patient access to insurance funding and encourage legislation on issues that threaten cancer patients' coverage for evolving therapies, therapeutic devices, or agents prescribed by their treating physicians.

Founding executive director Nancy Davenport-Ennis, a breast cancer survivor, said that the NPAF was instrumental in the passage of California Assembly Bill 1663, recently signed into law by Governor Pete Wilson. This bill outlines specific criteria for patient appeals when an HMO denies coverage.

Articles in this issue
Factor Analysis of New Symptom Scale in Breast Cancer Finds Six Clusters
AIDS Funding Increased for Fiscal '97
'Cancer Rates and Risks' Available
New Breast Cancer Patient Resource Is Available
Short-Term Metronidazole not Linked to Cancer
Various Capitation Models Are Available for Oncology Networks
NCI Urges full Disclosure of Cigarette Contents
Antifungal Resistance on the Increase
Fentanyl Patch Useful Alternative in Cancer Pain Patients
Analysis of Microvessel Density Predicts Extraprostatic Spread
Late Infection With Cytomegalovirus a Serious Problem in Bone Marrow Transplant Patients
FDA Panel Cancels HIV Drug Meeting
Klausner Cites Breast Cancer Progress in Jo Oberstar Lecture
Foundation Supports Legislation Backing Cancer Treatment Coverage
FDA Approves Xillix LIFE-Lung System

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.